Two ischemic stroke events within 48 h: a case report of an unusual presentation of thrombotic thrombocytopenic purpura

[1]  M. Ghabaee,et al.  Modified 8Ds algorithm improves door-to-needle time in patients with acute ischemic stroke eligible for alteplase or thrombectomy: A prospective Cohort study , 2021, Journal of Neurological Sciences.

[2]  J. Ferro,et al.  Cerebrovascular manifestations in hematological diseases: an update , 2021, Journal of Neurology.

[3]  X. Zheng,et al.  Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality , 2021, TH Open.

[4]  L. Pasalic,et al.  Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults , 2020, Seminars in Thrombosis and Hemostasis.

[5]  E. Tenison,et al.  Congenital thrombotic thrombocytopenic purpura presenting in adulthood with recurrent cerebrovascular events , 2019, BMJ Case Reports.

[6]  M. Streiff,et al.  Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. , 2019, Blood.

[7]  Pradeepthi Badugu,et al.  Atypical Thrombotic Thrombocytopenic Purpura Presenting as Stroke , 2019, Case reports in hematology.

[8]  D. Chauveau,et al.  Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. , 2018, Blood.

[9]  S. Olindo,et al.  Immune-Thrombotic Thrombocytopenic Purpura is a Rare Cause of Ischemic Stroke in Young Adults: Case Reports and Literature Review. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[10]  Johnson M Liu,et al.  Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura , 2018, BMJ Case Reports.

[11]  H. Erdoğan,et al.  Incidental Thrombotic Thrombocytopenic Purpura during Acute Ischemic Stroke and Thrombolytic Treatment. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[12]  P. Coppo.  Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[13]  M. Vicente-Pascual,et al.  Ischaemic stroke as the predecessor event of an episode of thrombotic thrombocytopenic purpura. , 2017, Neurología.

[14]  É. Azoulay,et al.  Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. , 2016, The Lancet. Haematology.

[15]  E. Lerma,et al.  Thrombotic thrombocytopenic purpura. , 2014, Disease-a-month : DM.

[16]  G. Procaccianti,et al.  Stroke due to typical thrombotic thrombocytopenic purpura treated successfully with intravenous thrombolysis and therapeutic plasma exchange , 2013, BMJ Case Reports.

[17]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[18]  P. Coppo,et al.  Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. , 2012, Presse medicale.

[19]  F. Nicoli,et al.  Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura , 2011, Journal of clinical apheresis.

[20]  S. Levine,et al.  Thrombophilias and Stroke: Diagnosis, Treatment, and Prognosis , 2005, Journal of Thrombosis and Thrombolysis.

[21]  L. Goodnough,et al.  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. , 2004, Blood.

[22]  A. Walker,et al.  Incidence of Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome , 2004, Epidemiology.

[23]  R. Sarode,et al.  Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident , 2004, Journal of clinical apheresis.

[24]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[25]  S. Vesely,et al.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. , 2003, Blood.

[26]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[27]  S. Nomura.  [Thrombotic thrombocytopenic purpura (TTP)]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[28]  A. Arboix,et al.  Cerebrovascular disease as the initial clinical presentation of haematological disorders. , 1997, European neurology.

[29]  R. Holman,et al.  Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991 , 1995, American journal of hematology.

[30]  E. Wijdicks,et al.  Stroke in relapsing thrombotic thrombocytopenic purpura. , 1991, Stroke.

[31]  A. Silverstein.  Thrombotic thrombocytopenic purpura. The initial neurologic manifestations. , 1968, Archives of neurology.